Events

Infosessions 'Strategic Goods Control department' (dCSG) on dual use and defence-related goods
FEB
Tue
25
NOV
Thu
20

Starts in 1 week ago

Location

Online an 1 physical session

Herman Teirlinckgebouw, Havenlaan 88, 1000 Brussel
Programmes
Security Digital, Industry & Space Digital Europe Cybersecurity Defence EDF NATO-EDA Space

The Strategic Goods Control department is again organizing training courses so you can become acquainted with the subject matter.

There will be several sessions:

  • 3 sessions of the basic training in defence-related goods: online on Tuesday 25 March, Tuesday 24 June and Tuesday 7 October each time from 10:00 AM to 11:30 AM.
  • 3 sessions of the basic dual use training, these will also take place online on February 25 and November 20 and there will also be a physical session on June 18 in our offices.

More info on the website of dCSG

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.